Overview: A cytokine-driven route to osimertinib resistance in EGFR-mutant NSCLC Osimertinib has transformed treatment for patients with EGFR-mutant non-small cell lung cancer (NSCLC) but resistance remains a critical hurdle. A combination of clinical data, tumor profiling, and functional studies now implicates IFITM3, a small antiviral membrane protein, in mediating resistance. The key finding is that…